- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04773639
Randomized Clinical Trial of a Multi-Modal Palliative Care Intervention
Adults diagnosed with metastatic cancer commonly experience depression and anxiety symptoms, which can interfere with advance care planning. This randomized clinical trial evaluates a novel, piloted, primary palliative care intervention that addresses advance care planning and psychosocial needs of patients with metastatic cancer. The intervention focuses on patients with elevated anxiety and depression (anx/dep) symptoms-those with highest psychosocial needs who may be at greatest risk for advance care planning non-completion. The intervention is founded on an evidence-based intervention approach known as Acceptance and Commitment Therapy (ACT) that reduces distress and promotes behavior change through theory-driven mechanisms. In the proposed randomized trial, M-ACT will be compared to a usual care control condition. The study will also assess the association between advance care planning and anx/dep symptoms, thereby informing the critical practice question of whether anx/dep symptoms should be addressed concurrently with advance care planning. The study will enroll patients with Stage IV solid tumor cancer (N=240) within Rocky Mountain Cancer Centers, randomized 1:1 to M-ACT or usual care. The study aims to: 1) Evaluate the hypothesis that M-ACT will increase advance care planning completion (primary outcome) and sense of life meaning, and reduce anx/dep symptoms and fear of dying relative to usual care control. 2) Assess the association between anx/dep symptoms and advance care planning at baseline and over time, testing the hypothesis that decreases in anx/dep symptoms at post- intervention will be associated with increases in advance care planning at follow-up. 3) Assess M-ACT's hypothesized mechanisms to specify how the intervention works (exploratory aim). Given their advance care planning and psychosocial needs, and poor access to palliative care, rigorously investigating M-ACT has the potential to benefit community patients with metastatic cancer and to advance palliative care science by addressing gaps in novel approaches, foundational knowledge, and the scalable delivery of palliative care.
Note: Due to the coronavirus pandemic, the in-person group component of M-ACT has currently been shifted to an online group format.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study will evaluate an innovative, multi-modal palliative care intervention that addresses the lack of advance care planning (ACP) and unmet psychosocial needs commonly experienced by patients with metastatic cancer. Up to half of adults with metastatic cancer report elevated anxiety or depression symptoms, which can cause withdrawal from daily activities and future planning and have been linked to non-adherent health behaviors in other disease populations. However, little is known about the extent to which anxiety or depression influence ACP completion in palliative care. In addition, metastatic cancer triggers patients' fear of dying and threatens their sense of meaning. The current approach aims to optimize two core palliative care outcomes - ACP and psychosocial well being - in outpatient oncology settings and to build the evidence base for primary palliative care interventions. This new multimodal intervention, which is based on extensive pilot data, uses a primary palliative care approach and focuses on patients with elevated anxiety or depression (anx/dep) symptoms.
The intervention is based on Acceptance and Commitment Therapy (ACT), an evidence-based approach to reduce distress and promote behavior change through theorized mechanisms that include cultivating acceptance of internal experience and aligning behavior with personal values. A pilot study for adults with metastatic cancer and elevated anx/dep symptoms conducted by the current research team, leveraged ACT to design and refine the multi-modal ACT intervention (M-ACT) in response to patient and provider feedback. M-ACT helps metastatic cancer patients to live meaningfully and face the future no matter what their health status, supports their engagement in ACP and addresses their psychosocial needs.
To facilitate future scalability, M-ACT uses a novel multi-modal delivery structure comprising both in-person group sessions led by existing on-site clinical social workers and self-paced, personalized online sessions completed at home, which efficiently increase intervention dose without increasing patient travel or provider demands. The current randomized controlled trial will rigorously evaluate the ability of M-ACT to increase ACP (primary outcome) and improve psychosocial outcomes (secondary). This study also will evaluate the relationship between anx/dep symptoms and ACP to inform the critical clinical question of whether anx/dep symptoms should be addressed concurrently with ACP. Finally, the study will explore mechanisms that may explain how M-ACT influences ACP and the targeted secondary outcomes.
The study will enroll patients with stage IV solid tumor cancer (N = 240), randomized in a 1:1 ratio to M-ACT or usual care for a 4-week intervention period. Outcomes will be assessed at baseline, mid-intervention (to assess mechanisms), 1-week post-intervention, and 2-month follow-up.
Note: Due to the coronavirus pandemic, the in-person group component of M-ACT has currently been shifted to an online group format.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Madeline Nealis, MPH
- Phone Number: 720-515-9461
- Email: archlab@colorado.edu
Study Contact Backup
- Name: Sarah Genung, BA
- Phone Number: 720-515-9461
- Email: archlab@colorado.edu
Study Locations
-
-
Colorado
-
Boulder, Colorado, United States, 80303
- Recruiting
- Rocky Mountain Cancer Centers
-
Contact:
- Jill Mitchell, MSW, PHD
- Email: Jill.Mitchell@usoncology.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- At least 18 years of age
- English-speaking (able to speak, read, and write well in English)
- Diagnosed with Stage IV metastatic cancer of any solid tumor type
- Capable at time of consent of understanding and voluntarily consenting themselves to the study, attending group sessions, and completing the online sessions at home, confirmed by an Eastern Cooperative Group Performance Status Scale of 0 to 2
- Endorse moderate to severe anxiety or depression symptoms on the Patient Health Questionnaire-4
Exclusion Criteria:
- Current high suicide risk
- Psychiatric hospitalization or suicide attempt in the past 5 years
- History of chronic, untreated trauma unrelated to their cancer
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Multi-Modal Acceptance and Commitment Therapy (M-ACT)
M-ACT consists of five 2-hour group sessions (plus booster) that alternate with self-paced online modules and check-ins that participants complete on their own, between the group sessions.
The intervention addresses distress associated with coping with metastatic cancer and supports engagement in advance care planning.
The intervention is based on Acceptance and Commitment Therapy, an intervention model that aims to help people cope with life challenges and difficult thoughts/feelings in a manner that helps them to live fuller and more meaningful lives.
|
An innovative muli-modal palliative care intervention that addresses the lack of advance care planning and unmet psychosocial needs commonly experienced by patients with metastatic cancer.
|
Other: Control: Usual Care
Patients in the control arm will have access to usual care (UC) at the collaborating clinics, consisting of access to a clinical social worker and nurse practitioners for advance care planning and supportive visits at patient request.
After completion of study procedures, including FU, the UC participants will be offered M-ACT free of cost.
|
The control condition includes usual care (UC) at the collaborating clinics, consisting of access to a clinical social worker and nurse practitioners for advance care planning and supportive visits at patient request.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in advance care planning
Time Frame: Assessed four times with parallel timing in the control group: prior to the intervention (Pre), week 3 of the intervention (Mid), within one week after the end of the weekly intervention (Post), at 2-month follow-up (FU)
|
The primary outcome is defined as change in the number of steps taken toward ACP completion from baseline through 2-month follow-up.
ACP steps will be assessed with a checklist adapted from the M-ACT pilot study by consulting the Hospice & Palliative Nurses Association online ACP resources and the study team, and refined by soliciting pilot participants' feedback on item clarity.
The checklist describes each ACP step and asks patients to indicate steps taken to date.
|
Assessed four times with parallel timing in the control group: prior to the intervention (Pre), week 3 of the intervention (Mid), within one week after the end of the weekly intervention (Post), at 2-month follow-up (FU)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient Health Questionnaire (PHQ-9)
Time Frame: Assessed four times with parallel timing in the control group: prior to the intervention (Pre), week 3 of the intervention (Mid), within one week after the end of the weekly intervention (Post), at 2-month follow-up (FU)
|
Patient-reported depression symptom questionnaire.
Higher scores = more depression symptoms
|
Assessed four times with parallel timing in the control group: prior to the intervention (Pre), week 3 of the intervention (Mid), within one week after the end of the weekly intervention (Post), at 2-month follow-up (FU)
|
Generalized Anxiety Disorder-7
Time Frame: Assessed four times with parallel timing in the control group: prior to the intervention (Pre), week 3 of the intervention (Mid), within one week after the end of the weekly intervention (Post), at 2-month follow-up (FU)
|
Patient-reported anxiety symptom questionnaire.
Higher scores = more anxiety symptoms
|
Assessed four times with parallel timing in the control group: prior to the intervention (Pre), week 3 of the intervention (Mid), within one week after the end of the weekly intervention (Post), at 2-month follow-up (FU)
|
The Death Attitude Profile - Revised, Fear of Death and Death Avoidance Scales
Time Frame: Assessed four times with parallel timing in the control group: prior to the intervention (Pre), week 3 of the intervention (Mid), within one week after the end of the weekly intervention (Post), at 2-month follow-up (FU)
|
Patient-reported fear of death and dying questionnaire.
Higher scores = greater fear of death and dying
|
Assessed four times with parallel timing in the control group: prior to the intervention (Pre), week 3 of the intervention (Mid), within one week after the end of the weekly intervention (Post), at 2-month follow-up (FU)
|
Functional Assessment of Chronic Illness Therapy (FACIT), Meaning/Peace Subscale
Time Frame: Assessed four times with parallel timing in the control group: prior to the intervention (Pre), week 3 of the intervention (Mid), within one week after the end of the weekly intervention (Post), at 2-month follow-up (FU)
|
Patient-reported sense of life meaning and peace.
Higher scores = greater sense of meaning/peace
|
Assessed four times with parallel timing in the control group: prior to the intervention (Pre), week 3 of the intervention (Mid), within one week after the end of the weekly intervention (Post), at 2-month follow-up (FU)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intervention Acceptability: Session Feedback Questionnaire
Time Frame: At the end of each session during the 5-week intervention period, plus after the booster session 1 month later
|
Participant value of the session will be assessed through the Session Feedback.
Higher scores = higher value and acceptability of the session
|
At the end of each session during the 5-week intervention period, plus after the booster session 1 month later
|
Intervention Acceptability: Group session attendance and online session completion
Time Frame: From the start to end of the 5-week intervention plus the booster session held 1 month later
|
Intervention engagement will be assessed via attendance in group sessions and completion of the online modules and check-ins
|
From the start to end of the 5-week intervention plus the booster session held 1 month later
|
Intervention Acceptability: Client Satisfaction Questionnaire-8
Time Frame: Assessed two times: within one week after the end of the weekly intervention (Post), at 2-month follow-up (FU)
|
Participant satisfaction will be measured using the Client Satisfaction Questionnaire-8 (adapted to the current intervention) with higher scores indicating more satisfaction
|
Assessed two times: within one week after the end of the weekly intervention (Post), at 2-month follow-up (FU)
|
Process measure: Multidimensional Experiential Avoidance Scale: Denial and Distress Aversion scales
Time Frame: Assessed four times with parallel timing in the control group: prior to the intervention (Pre), week 3 of the intervention (Mid), within one week after the end of the weekly intervention (Post), at 2-month follow-up (FU)
|
Patient-reported experiential avoidance with higher scores indicating greater avoidance.
|
Assessed four times with parallel timing in the control group: prior to the intervention (Pre), week 3 of the intervention (Mid), within one week after the end of the weekly intervention (Post), at 2-month follow-up (FU)
|
Process Measure: Experiences Questionnaire-Decentering Scale
Time Frame: Assessed four times with parallel timing in the control group: prior to the intervention (Pre), week 3 of the intervention (Mid), within one week after the end of the weekly intervention (Post), at 2-month follow-up (FU)
|
Patient-reported defusion/decentering with higher scores indicating greater defusion/decentering.
|
Assessed four times with parallel timing in the control group: prior to the intervention (Pre), week 3 of the intervention (Mid), within one week after the end of the weekly intervention (Post), at 2-month follow-up (FU)
|
Process Measure: Valuing Questionnaire
Time Frame: Assessed four times with parallel timing in the control group: prior to the intervention (Pre), week 3 of the intervention (Mid), within one week after the end of the weekly intervention (Post), at 2-month follow-up (FU)
|
Patient-reported values-aligned behavior with higher scores indicating more aligned behavior
|
Assessed four times with parallel timing in the control group: prior to the intervention (Pre), week 3 of the intervention (Mid), within one week after the end of the weekly intervention (Post), at 2-month follow-up (FU)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Joanna J Arch, PHD, University of Colorado, Boulder
Publications and helpful links
General Publications
- Arch JJ, Fishbein JN, Ferris MC, Mitchell JL, Levin ME, Slivjak ET, Andorsky DJ, Kutner JS. Acceptability, Feasibility, and Efficacy Potential of a Multimodal Acceptance and Commitment Therapy Intervention to Address Psychosocial and Advance Care Planning Needs among Anxious and Depressed Adults with Metastatic Cancer. J Palliat Med. 2020 Oct;23(10):1380-1385. doi: 10.1089/jpm.2019.0398. Epub 2020 Jan 6.
- Arch JJ, Mitchell JL, Schmiege SJ, Levin ME, Genung SR, Nealis MS, Fink RM, Bright EE, Andorsky DJ, Kutner JS. A randomized controlled trial of a multi-modal palliative care intervention to promote advance care planning and psychological well-being among adults with advanced cancer: study protocol. BMC Palliat Care. 2022 Nov 17;21(1):198. doi: 10.1186/s12904-022-01087-z.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19-0787
- R01NR018479 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Cancer
-
Gustave Roussy, Cancer Campus, Grand ParisCompletedGIST Metastatic Cancer | Breast Metastatic Cancer | Kidney Metastatic Cancer | Colon Metastatic Cancer | Rectal Metastatic CancerFrance
-
Orion Biotechnology Polska Sp. z o.o.Not yet recruitingMetastatic Colorectal Cancer | Metastatic Cancer | Metastatic Breast Cancer | Metastatic Urothelial Carcinoma | Metastatic Gastric Cancer | Metastatic Pancreatic Cancer
-
Gottfried MayaUnknownMetastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Prostate Cancer | Metastatic Gastric Cancer | Metastatic Bladder CancerIsrael
-
Albert Einstein College of MedicineTerminatedCancer | Solid Tumor | Metastatic Solid Tumor | Metastatic dMMR Solid CancerUnited States
-
Institut de Cancérologie de la LoireSaint-Louis Hospital, Paris, France; Gustave Roussy, Cancer Campus, Grand ParisWithdrawnMetastatic Colorectal Cancer | Metastatic Breast Cancer | Metastatic Head and Neck CancerFrance
-
Cedars-Sinai Medical CenterRecruitingNeoplasms | Cancer | Cancer, MetastaticUnited States
-
Advaxis, Inc.TerminatedMetastatic Melanoma | Urothelial Carcinoma | Metastatic Non-Small Cell Lung Cancer | Head and Neck Cancer Metastatic | Colon Cancer MetastaticUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Cota Inc.Blue Cross Blue Shield; NantHealth Inc.TerminatedPancreatic Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Melanoma | Metastatic Prostate Cancer | Metastatic Colon CancerUnited States
-
Oslo University HospitalVestre Viken Hospital Trust; University Hospital of North Norway; Ostfold Hospital... and other collaboratorsRecruitingCancer MetastaticNorway
Clinical Trials on Multi-Modal Palliative Care Intervention
-
University Hospitals of Derby and Burton NHS Foundation...University of Hull; Sheffield Teaching Hospitals NHS Foundation Trust; University... and other collaboratorsRecruitingExercise | Breast Neoplasm FemaleUnited Kingdom
-
Taipei Medical University Shuang Ho HospitalRecruiting
-
The Integrative Care Science CenterUniversity Hospital, Linkoeping; EkhagastiftelsenUnknown
-
The Cleveland ClinicMichael J. Fox Foundation for Parkinson's ResearchCompletedParkinson DiseaseUnited States
-
University of KansasEunice Kennedy Shriver National Institute of Child Health and Human Development...Unknown
-
McMaster UniversityHamilton Health Sciences CorporationCompletedKnee Osteoarthritis | Hip OsteoarthritisCanada
-
Charite University, Berlin, GermanyKliniken Essen-MitteRecruitingFallopian Tube Cancer | Frailty | Ovary Cancer | Peritoneum CancerGermany
-
University Hospital, LilleNovartis; Santelys AssociationTerminatedLung Cancer MetastaticFrance
-
University of Dublin, Trinity CollegeSt. James's Hospital, Ireland; Irish Cancer SocietyCompleted
-
Massachusetts General HospitalAmerican Society of Clinical OncologyCompletedNon-small Cell Lung CancerUnited States